Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates Posted byZacks Equity Research November 2, 2021 Leave a comment on Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?